GlassScriptPhysician profile
Jonathan Gold
NPI 1073580023
$6,975.44
in general payments reported to CMS, 2019-2025
37 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $491 · 2021: $795 · 2022: $1,136 · 2023: $1,299 · 2024: $1,030 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.18 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $815.15 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $794.71 | 2019-2025 | |
| Boston Scientific Corporation | $680.66 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $568.10 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $455.89 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $355.99 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $343.24 | 2021-2025 | Camzyos, Eliquis |
| Abiomed | $295.24 | 2022-2023 | Impella |
| Impulse Dynamics (USA) INC. | $273.92 | 2021-2025 | Optimizer, Optimizer |
| Amarin Pharma, INC. | $261.92 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $259.46 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $231.22 | 2024-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $219.35 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.72 | 2019-2025 | Lifevest |
| Astellas Pharma US INC | $168.51 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $160.72 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $117.77 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $81.88 | 2019-2024 | Evkeeza |
| Lundbeck LLC | $79.78 | 2019 | |
| Vital Connect, INC | $76.07 | 2023 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $71.62 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $61.89 | 2019-2020 | |
| Atricure, INC. | $56.57 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.14 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $53.99 | 2022 | |
| Altathera Pharmaceuticals LLC | $37.61 | 2022-2023 | Sotalol Hydrochloride |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.18 | 2025 | Jardiance |
| W. L. Gore & Associates, INC. | $25.02 | 2019 | |
| Abbott Laboratories | $23.18 | 2022 | |
| Heartflow, INC. | $18.66 | 2025 | |
| Teleflex LLC | $18.62 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $16.44 | 2023 | Arcalyst |
| Althera Pharmaceuticals LLC | $16.21 | 2021 | |
| Medtronic Vascular, INC. | $15.79 | 2020 | |
| Pfizer INC. | $15.12 | 2025 | |
| Chiesi USA, INC. | $12.18 | 2019 | |
| Terumo Medical Corporation | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.